Ophthalmologists, Patients Hesitate to Switch to Anti-VEGF Biosimilars
HCPLive
JULY 28, 2024
Hesitancy with anti-VEGF biosimilars was identified in a survey among both ophthalmologists and patients with nAMD in Canada.
HCPLive
JULY 28, 2024
Hesitancy with anti-VEGF biosimilars was identified in a survey among both ophthalmologists and patients with nAMD in Canada.
Heart Sisters
JULY 28, 2024
Heart patients with persistent or recurrent post-stent chest pain present “an unmet clinical need”, according to the European Journal of Cardiology.
Med Page Today
JULY 28, 2024
(MedPage Today) -- People with HIV who took the antiretroviral drug abacavir (Ziagen) had an increased risk of major adverse cardiovascular events (MACE), according to an exploratory analysis of the REPRIEVE trial. Past use of abacavir increased.
HCPLive
JULY 28, 2024
Most men (91.7%) and women (72.7%) with psoriatic arthritis exhibited sexual dysfunction.
Nature Reviews - Cardiology
JULY 28, 2024
Nature Reviews Cardiology, Published online: 29 July 2024; doi:10.1038/s41569-024-01066-2 A new small-molecule inhibitor of vasohibins reduces myocardial stiffness and improves diastolic relaxation in a rat model of HFpEF.
CardiacWire
JULY 28, 2024
Edwards Lifesciences is going all-in on structural heart and heart failure, acquiring aortic valve-maker JenaValve Technology and implantable heart failure monitor company Endotronix for $1.2B and up to $445M in milestone payments. These two acquisitions could impact Edwards’ structural heart and heart failure portfolios in unique and meaningful ways… JenaValve’s Trilogy TAVR system doesn’t yet have FDA approval, but is CE Marked for both aortic regurgitation and aortic stenosis, which is notabl
Cardiovascular Diabetology
JULY 28, 2024
Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) have demonstrated efficacy in improving mortality and cardiovascular (CV) outcomes. However, the impact of GLP-1RAs therapy on cardiorenal outcomes of diabe.
Cardiovascular Update brings together the best content for cardiovascular medicine professionals from the widest variety of industry thought leaders.
Cardiology Update
JULY 28, 2024
A recent study published in JACC: Cardiovascular Interventions has provided new insights into the long-term management of patients suffering from recurrent in-stent restenosis (ISR), a condition presenting notable challenges in cardiovascular treatment. With minimal data and guidelines available for repeat percutaneous coronary interventions (PCI), this research offers valuable guidance for clinicians.
HCPLive
JULY 28, 2024
These findings support delgocitinib’s clinical benefit as a possible medication option for individuals with moderate to severe chronic hand eczema.
Cardiovascular Diabetology
JULY 28, 2024
The neutral result of the PROMINENT trial has led to questions about the future for pemafibrate. This commentary discusses possible reasons for the lack of benefit observed in the trial. There were, however, i.
Circulation
JULY 28, 2024
Circulation, Volume 150, Issue 5 , Page 390-392, July 30, 2024.
Journal of Cardiovascular Pharmacology
JULY 28, 2024
An abstract is unavailable. This article is available as a PDF only.
Circulation
JULY 28, 2024
Circulation, Volume 150, Issue 5 , Page 347-349, July 30, 2024.
Circulation
JULY 28, 2024
Circulation, Volume 150, Issue 5 , Page e105-e105, July 30, 2024.
Frontiers in Cardiovascular Medicine
JULY 28, 2024
IntroductionMyocardial calcifications (MC) represent a relatively rare pathological process, which may accompany different cardiovascular conditions and can be broadly categorized as dystrophic or metastatic. Myocardial infarction (MI) has been traditionally regarded as the main cause of MC overall; however, no updated comprehensive data on the relative incidence of different forms of MC is available.
Circulation
JULY 28, 2024
Circulation, Volume 150, Issue 5 , Page e102-e103, July 30, 2024.
Journal of Cardiothoracic Surgery
JULY 28, 2024
Lung cancer, which is diagnosed two to three times more frequently in patients over the age of 70, is a leading cause of cancer-specific mortality. Given the elevated risk of morbidity and mortality, surgical.
Circulation
JULY 28, 2024
Circulation, Volume 150, Issue 5 , Page e104-e104, July 30, 2024.
Let's personalize your content